Birzeit Pharmaceuticals Company

PLSE:BPC Stock Report

Market Cap: US$145.0m

Birzeit Pharmaceuticals Valuation

Is BPC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BPC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BPC ($3.74) is trading above our estimate of fair value ($0.07)

Significantly Below Fair Value: BPC is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BPC?

Key metric: As BPC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BPC. This is calculated by dividing BPC's market cap by their current earnings.
What is BPC's PE Ratio?
PE Ratio40.5x
EarningsUS$3.58m
Market CapUS$144.98m

Price to Earnings Ratio vs Peers

How does BPC's PE Ratio compare to its peers?

The above table shows the PE ratio for BPC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.5x
JPH Jerusalem Pharmaceuticals
15.7xn/aUS$64.4m
PHARMACARE Dar Al-Shifa Pharmaceuticals
6.2xn/aUS$30.2m
BJP Beit Jala Pharmaceutical
15.3xn/aد.أ19.6m
SEARL Searle
40.9xn/aPK₨40.2b
BPC Birzeit Pharmaceuticals
40.5xn/aUS$145.0m

Price-To-Earnings vs Peers: BPC is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the peer average (24x).


Price to Earnings Ratio vs Industry

How does BPC's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BPC 40.5xIndustry Avg. 24.0xNo. of Companies73PE020406080100+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BPC is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the Asian Pharmaceuticals industry average (24.1x).


Price to Earnings Ratio vs Fair Ratio

What is BPC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BPC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio40.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BPC's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies